Tags : Asset

M&A

Fusion to Acquire Ipsen’s IPN-1087 to Expand its Pipeline of

Shots: Ipsen to receive 400,000 shares at closing and an additional 200,000 shares as milestones, $81.63M as development and regulatory milestones & $423.24M as commercial milestones along with royalties on net sales Fusion will be responsible for paying to a third-party licensor up to $84.7M in development milestones and royalties on net sales of products […]Read More